c-MET (M1250I)
Sign in to save this workspaceMET · Variant type: point · HGVS: p.M1250I
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Crizotinib | 97.3% | 2.7% | 91.39 |
| 2 | Capmatinib | 96.8% | 3.2% | 99.75 |
| 3 | Tepotinib | 95.6% | 4.4% | 99.75 |
| 4 | Cabozantinib | 94.7% | 5.3% | 92.73 |
| 5 | Deucravacitinib | 92.1% | 7.9% | 98.99 |
| 6 | Gilteritinib | 81.7% | 18.3% | 88.97 |
| 7 | Erdafitinib | 74.1% | 25.9% | 95.71 |
| 8 | Pacritinib | 70.1% | 29.9% | 88.64 |
| 9 | Tivozanib | 68.3% | 31.7% | 92.42 |
| 10 | Lenvatinib | 52.3% | 47.7% | 97.74 |
| 11 | Defactinib | 51.2% | 48.8% | 92.68 |
| 12 | Vemurafenib | 47.0% | 53.0% | 96.49 |
| 13 | Fostamatinib | 41.2% | 58.8% | 96.74 |
| 14 | Dacomitinib | 38.3% | 61.7% | 97.99 |
| 15 | Canertinib | 36.1% | 63.9% | 96.49 |
| 16 | Repotrectinib | 34.3% | 65.7% | 84.21 |
| 17 | Abemaciclib | 29.0% | 71.0% | 91.48 |
| 18 | Neratinib | 27.2% | 72.8% | 93.18 |
| 19 | Pazopanib | 26.5% | 73.5% | 97.49 |
| 20 | Dabrafenib | 21.7% | 78.3% | 94.74 |
| 21 | Fedratinib | 17.7% | 82.3% | 96.21 |
| 22 | Entrectinib | 17.3% | 82.7% | 93.69 |
| 23 | Selpercatinib | 15.0% | 85.0% | 96.72 |
| 24 | Afatinib | 14.6% | 85.4% | 98.50 |
| 25 | Sunitinib | 12.9% | 87.1% | 91.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Crizotinib | 97.3% | — | — |
| Capmatinib | 96.8% | — | — |
| Tepotinib | 95.6% | — | — |
| Cabozantinib | 94.7% | — | — |
| Deucravacitinib | 92.1% | — | — |
| Gilteritinib | 81.7% | — | — |
| Erdafitinib | 74.1% | — | — |
| Pacritinib | 70.1% | — | — |
| Tivozanib | 68.3% | — | — |
| Lenvatinib | 52.3% | — | — |
| Defactinib | 51.2% | — | — |
| Vemurafenib | 47.0% | — | — |
| Fostamatinib | 41.2% | — | — |
| Dacomitinib | 38.3% | — | — |
| Canertinib | 36.1% | — | — |
| Repotrectinib | 34.3% | — | — |
| Abemaciclib | 29.0% | — | — |
| Neratinib | 27.2% | — | — |
| Pazopanib | 26.5% | — | — |
| Dabrafenib | 21.7% | — | — |
| Fedratinib | 17.7% | — | — |
| Entrectinib | 17.3% | — | — |
| Selpercatinib | 15.0% | — | — |
| Afatinib | 14.6% | — | — |
| Sunitinib | 12.9% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.0ms